Imipenem-cilastatin-relebactam Injection
FDA Identified Breakpoints
|
|
Minimum Inhibitory |
Disk Diffusion a |
||||
|---|---|---|---|---|---|---|
|
Pathogen |
S |
I |
R |
S |
I |
R |
|
Enterobacteriaceae b |
M-100 standard is recognized |
|||||
|
Pseudomonas aeruginosa |
M-100 standard is recognized |
|||||
|
Acinetobacter calcoaceticus-baumannii complex |
≤2/4 |
4/4 |
≥8/4 |
- |
- |
- |
|
Haemophilus influenzae |
≤4/4 |
- |
- |
- |
- |
- |
|
Anaerobes c,d |
M-100 standard is recognized |
- |
- |
- |
||
S = Susceptible; I = Intermediate; R = Resistant
a For disk diffusion, use paper disks impregnated with imipenem/relebactam at a concentration of 10/25 mcg/mL.
b Clinical efficacy was shown for Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Klebsiella oxytoca.
c Clinical efficacy was shown for Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Fusobacterium nucleatum, Parabacteroides distasonis.
d Agar dilution method.